Levothyroxine Sodium Preparation via Copper Complex Coupling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing Levothyroxine Sodium are inefficient, costly, and generate genotoxic impurities, making them unsuitable for industrial-scale production and multikilo manufacturing, with high expenses, pressure reactions, and concerns over product purity.
Innovation Solution
A process using 3,5-Diiodo L-Tyrosine copper complex and novel Bis(p-anisyl)iodonium Iodide as intermediates, involving coupling, demethylation, and iodination steps, to produce high-purity Levothyroxine Sodium without genotoxic impurities, adaptable for industrial-scale production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If current methods for producing Levothyroxine Sodium are used, then production can be achieved, but the process is inefficient, costly, and generates genotoxic impurities
Solution Approach 1:
The invention extracts and eliminates the harmful genotoxic impurities (brominated compounds) from the synthesis process by replacing the traditional iodinating agent that generates these impurities with an alternative approach using N-iodosuccinimide and oxidizing agents, thereby achieving high purity product without genotoxic contaminants
Solution Approach 2:
The invention changes the chemical parameters of the synthesis process by using specific reagents (N-iodosuccinimide, oxidizing agents like hydrogen peroxide or sodium hypochlorite) and controlling pH and temperature parameters to achieve selective iodination without forming genotoxic impurities, thereby improving product purity
2Ease of manufacture
If pressure reactions are used in current methods, then coupling reactions can be achieved, but the process becomes complex and costly for industrial-scale production
Solution Approach 1:
The invention uses readily available, inexpensive reagents such as N-iodosuccinimide, hydrogen peroxide, and sodium hypochlorite that do not require special handling or expensive equipment, making the process simple and suitable for industrial-scale production without complex pressure reaction conditions
3Manufacturing precision
If traditional synthesis methods are used, then Levothyroxine Sodium can be produced, but with high expenses and concerns over product purity
Solution Approach 1:
The invention employs reagents that are self-indicating or easily monitored (such as color changes during iodination) and requires minimal purification steps, reducing both cost and complexity while ensuring high product purity through inherently cleaner reaction chemistry
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves a high yield of 99.9% pure Levothyroxine Sodium with minimal Liothyronine impurities (0.04%), reducing costs and overcoming previous methods' inefficiencies and impurity issues, making it economically and industrially feasible.
Implementation Method 1
Coupling reaction between 3, 5-diiodo L-Tyrosine copper complex and novel Bis (p-anisyl) iodonium iodide in the presence of Diisopropylamine or other organic bases in n-Butanol or other alcoholic solvents to obtain 2-Amino-3-(3,5-diiodo-4-(4-methoxy phenoxy)phenyl)propanoic acid
Implementation Method 2
Demethylation of 2-Amino-3-(3,5-diiodo-4-(4-methoxyphenoxy)phenyl)propanoic acid using a mixture of Acetic acid and Hydroiodic acid to obtain 3,5-diiodothyronine
Implementation Method 3
Iodinizing 3,5-diiodothyronine with methanolic or other alcoholic monomethylamine and Iodine to obtain Levothyroxine
Data Source
AI summary
The present invention provides a novel process for the preparation of highly pure Levothyroxine Sodium, i.e., (S)-2-amino-3-[4-(4-hydroxy-3, 5-diiodophenoxy)-3,5-diiodophenyl] propanoic acid sodium salt via two process intermediates viz 3,5-Diiodo L-Tyrosine copper complex and novel Bis (p-anisyl) iodonium Iodide. The invention also provides levothyroxine pentahydrate free from genotoxic impurities and liothyronine levels below 0.04% wt/wt.